“Within that health care boom, there is a sub boom, which is oncology. When you think of oncology, two modalities come to mind. The first is chemo, external beam radiation, which is brutal. It fries your body. The second is chemotherapy, which is also brutal. It poisons your entire body.”
He explained that after more than 80 years of working with those two technologies, the field of cancer medicine is ripe for disruption. He sees radionuclide therapy, cell-based cancer treatment, and peptide receptor therapy as possible avenues for progress.
According to Lee-Chin, it’s fundamentally crucial for investors to understand what they’re putting their money behind. Since the partnership with CNL is not a speculative play where the stakes are just about portfolio gains or losses, his firm has also taken on a chief medical officer as well as a chief scientific officer.
“We have populated our team with individuals who have domain scientific and medical expertise at the highest level,” he said. “We already have invested in one company over €225 million. That’s how committed we are.”
The video of Michael Lee Chin’s interview with WP can be viewed here.
